Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Letai

Showing results (131-140 of 182) with videos related to

Pageof 19
Sort By:
The Journal of Clinical Investigation|August 23, 2019
DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistanceKatsuhiro Togami, Timothy Pastika, Jason Stephansky, et al.
Blood|April 13, 2016
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanismMary Ann Anderson, Jing Deng, John F Seymour, et al.
Elife|June 1, 2017
Synergistic interactions with PI3K inhibition that induce apoptosisYaara Zwang, Oliver Jonas, Casandra Chen, et al.
Blood|November 19, 2011
P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironmentAbdel Kareem Azab, Phong Quang, Feda Azab, et al.
Cancers|March 6, 2021
Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 ProfilingRyan N Rys, Claudia M Wever, Dominique Geoffrion, et al.
Nature|December 2, 2016
Genomic evolution and chemoresistance in germ-cell tumoursAmaro Taylor-Weiner, Travis Zack, Elizabeth O'Donnell, et al.
Nature Cancer|December 23, 2021
Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatmentCatherine Gutierrez, Aziz M Al'Khafaji, Eric Brenner, et al.
Cancer Discovery|August 14, 2016
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous LeukemiaMarina Konopleva, Daniel A Pollyea, Jalaja Potluri, et al.
JCI Insight|August 9, 2019
Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumorMichael V Ortiz, Saima Ahmed, Melissa Burns, et al.
Cell Death & Disease|July 31, 2019
Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signalingFelix Seyfried, Salih Demir, Rebecca Louise Hörl, et al.
Pageof 19

Showing results (131-140 of 182) with videos related to

Sort By:
Pageof 19
The Journal of Clinical Investigation|August 23, 2019
DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistanceKatsuhiro Togami, Timothy Pastika, Jason Stephansky, et al.
Blood|April 13, 2016
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanismMary Ann Anderson, Jing Deng, John F Seymour, et al.
Elife|June 1, 2017
Synergistic interactions with PI3K inhibition that induce apoptosisYaara Zwang, Oliver Jonas, Casandra Chen, et al.
Blood|November 19, 2011
P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironmentAbdel Kareem Azab, Phong Quang, Feda Azab, et al.
Cancers|March 6, 2021
Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 ProfilingRyan N Rys, Claudia M Wever, Dominique Geoffrion, et al.
Nature|December 2, 2016
Genomic evolution and chemoresistance in germ-cell tumoursAmaro Taylor-Weiner, Travis Zack, Elizabeth O'Donnell, et al.
Nature Cancer|December 23, 2021
Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatmentCatherine Gutierrez, Aziz M Al'Khafaji, Eric Brenner, et al.
Cancer Discovery|August 14, 2016
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous LeukemiaMarina Konopleva, Daniel A Pollyea, Jalaja Potluri, et al.
JCI Insight|August 9, 2019
Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumorMichael V Ortiz, Saima Ahmed, Melissa Burns, et al.
Cell Death & Disease|July 31, 2019
Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signalingFelix Seyfried, Salih Demir, Rebecca Louise Hörl, et al.
Pageof 19